UK's MHRA green-lights Ph I trial of BioVex herpes vacc
BioVex, a privately-held US biotechnology company, says that the UK Medicines and Healthcare Products Regulatory Agency (MHRA) has accepted its clinical trial application to conduct a Phase I study testing the safety and immunogenicity of its lead product, the infectious candidate vaccine for genital herpes, ImmunoVEX HSV2.
Preclinical studies suggest that the product prevented all symptoms of genital herpes and also triggered a strong immune response. ImmunoVEX HSV2 is a novel, live attenuated vaccine that has been designed to remove the genes that enable the herpes virus to avoid immune system detection. By removing the virus' ability to hide itself, the immune response is able to first recognize and then mount a response against the virus.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze